The ABATE trial is studying the effects of a study vaccine named ACI-24.060 in people with early Alzheimer’s disease. A build-up of protein Abeta (Aβ) in the brain is believed to play an important role in cognitive decline in Alzheimer’s disease. ACI-24.060 is designed to help reduce the quantity of ... Read More
Part II of the ABATE Study explores the effect of a new vaccine called ACI-24.060 on people with Down’s syndrome. People with Down’s syndrome have an increased risk of developing Alzheimer’s Disease. Alzheimer’s disease is caused by an increased level of ABeta (Aβ) protein leading to slowing down ... Read More
Scientists know that two proteins—amyloid beta (Aβ) and tau—build up in the brains of people with Alzheimer’s disease (AD). When tau accumulates abnormally, it forms tangles inside brain cells, which are strongly linked to symptom severity. The study drug is being investigated to determine ... Read More
The Oxford Brain Heath Clinic (BHC) is a new integrated research and clinical environment. It is dedicated to preparing clinical services for the 21st century to preserve brain health. The clinic was launched in August 2020, as a pilot, to improve the assessment and diagnosis of memory problems. At ... Read More
The CVHB937A12201 Study is looking to find out more about an investigational medication (called a study drug) in people with mild AD. We want to look at the study drug to see if it has an effect on a person’s ability to think and remember, and causes serious side effects. To do this, the study ... Read More
The DFP study aims to create a database of different measures taken by people at risk of Alzheimer’s disease. The measures include regular brain scans, cognitive and memory tests, scans of magnetic fields generated by the brain, retinal imaging, blood tests, and the use of wearable technology to ... Read More
The ISAP Study led in collaboration between the Diabetes Trial Unit and the Department of Psychiatry at the University of Oxford and Novo Nordisk will examine whether semaglutide, a tablet used to treat diabetes, can change the course of the earliest changes that happen in the brains of people at ... Read More
Alzheimer’s disease begins long before symptoms show. The ReTain study is evaluating whether an investigational medication is safe, tolerable and effective at slowing the onset of Alzheimer’s disease symptoms for those who may be at risk. ... Read More
This trial is testing an investigational medication in people who have early Alzheimer’s disease. Researchers want to learn about the safety of the investigational medication and how well it may work to slow the progression of Alzheimer’s disease. ... Read More
The WN45447 study aims to determine if an experimental drug can help slow down Alzheimer’s disease. WN45447 will include approximately 800 adults who have a recent diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease. Mild cognitive impairment means having problems with ... Read More
